Hutchison China Meditech Ltd. (Chi-Med) has scored the first approval in China of a fully domestically developed anticancer drug, with a nod for Elunate (fruquintinib) from the country's newly renamed National Medical Products Administration of China (NMPA, formerly CFDA).
The oral, highly selective small molecule inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 is indicated for metastatic colorectal cancer patients who have failed at least two prior systemic chemotherapies including fluoropyrimidine, oxaliplatin and irinotecan,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?